Search - tctmd.com

Displaying 21 - 40 of 55

Sort: Relevancy | Date

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

News Conference News ACC 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

Yael L. Maxwell

March 20, 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

News Conference News ISC 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

March 01, 2017

AHA Wades Into Conversation Over Periprocedural Use of Non-Vitamin K Antagonist Oral Anticoagulants

News Daily News

AHA Wades Into Conversation Over Periprocedural Use of Non-Vitamin K Antagonist Oral Anticoagulants

Yael L. Maxwell

February 13, 2017

News Features

Quit This, Start That: How Common New Year’s Resolutions Impact the Heart

January 20, 2017

News Features

Be It Resolved: As Evidence Mounts in Favor of a Brain-Heart Connection, Stress Should Be on the Radar During CVD Diagnosis

Yael L. Maxwell

January 16, 2017

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

November 21, 2016

News Conference News ESC 2016

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

August 31, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News Stories for 2015

December 29, 2015

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

December 29, 2015

News Opinion Editor's Corner

My Takeaways From AHA 2015

November 18, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Industry News

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA®

November 09, 2014

News Daily News

MADIT-CRT: Resynchronization Ups Survival in Patients with Mild Heart Failure and LBBB

April 03, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.